Leem to fight French med ed tax and sales rep limits; Prescrire wants public clinical trials
This article was originally published in Scrip
The planned root-and-branch reform of the French medicines regulatory system has been generally welcomed as overdue and pretty much in line with trends at European level, such as the shift to more transparency in procedures and towards requiring comparative trials for new drug approvals.
You may also be interested in...
France has announced a number of emergency measures to protect drug supplies threatened by the spread of the coronavirus.
A number of countries are resorting to extreme measures such as export bans to preserve stocks of medicines for the COVID-19 pandemic. Belgium is among the latest to impose an export prohibition, but might it fall foul of the EU’s export regulations?
In addition to our daily in-depth coverage of key events relating to the COVID-19 pandemic, we’re bringing you a periodic round-up of other developments. This edition covers Europe and other countries.